Moxifloxacin Outperforms Azithromycin in M genitalium Cure
A recent study found that moxifloxacin is more effective than azithromycin for treating Mycoplasma genitalium infections. The trial involved 358 patients and demonstrated higher microbiologic cure rates with moxifloxacin. Researchers suggest it could be a first-line treatment where resistance testing is not available.
- ▪A 10-day regimen of moxifloxacin yielded significantly higher cure rates than a 6-day regimen of azithromycin.
- ▪The study was conducted at a tertiary care hospital in Italy from January 2018 to June 2024.
- ▪Among symptomatic patients, the cure rate was 85.7% with moxifloxacin compared to 56.8% with azithromycin.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/moxifloxacin-outperforms-azithromycin-m-genitalium-cure-2026a1000gm2?src=rss |
| Publication time | Mon, 25 May 2026 08:00:00 EDT |
| Retrieval time | 2026-05-25T12:07:36.708Z |
| Last seen | 2026-05-25T12:07:36.708Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | wtFRc5bGZXHk |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:In patients with Mycoplasma genitalium (MG) infection, a 10-day regimen of moxifloxacin 400 mg daily yielded significantly higher microbiologic cure rates than a 6-day regimen of azithromycin 500 mg daily, supporting its use as a potential first-line treatment where resistance testing is unavailable.METHODOLOGY:Researchers conducted a phase 4 trial at a tertiary care hospital in Italy from January 2018 to June 2024 to demonstrate the superiority of moxifloxacin over azithromycin for treating MG infection in the absence of resistance testing.Overall, 358 patients with MG infection (median age, 36 years; 96.6% men) detected using multiplex polymerase chain reaction were randomly assigned to receive either moxifloxacin 400 mg once daily for 10 days (n = 193) or azithromycin 500 mg…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
